Compare Supplements

Side-by-side comparison of 1 supplements

Tes5.0

Tesamorelin

Limited safety

Evidence

Evidence Score5/10

Studies: 12

Meta-analyses: 1

Dosage & timing

Dosage:

Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base.

Best Time:

Any time

Can take on empty stomach

Form:

Egrifta / Egrifta SV (prescription, via a clinician)

What you'll notice

🔥 Visceral fat reduction (phase-3 RCTs, HIV lipodystrophy)positive

26-52 weeks

🫁 Liver fat reduction (RCTs in HIV-associated NAFLD)positive

6-12 months

🔄 Benefit reverses on discontinuation (trade-off)trade-off

Within months of stopping

Safety

Limited safety

Contraindications:

Active malignancy — tesamorelin raises IGF-1, a theoretical proliferative/neoplasia concern; it is contraindicated in active cancer
Pregnancy — contraindicated; GH/IGF-1 stimulation is inappropriate in pregnancy
Disruption of the hypothalamic-pituitary axis (hypophysectomy, pituitary tumor/surgery/radiation, head irradiation) per the approved label

Drug Interactions:

Insulin / glucose-lowering drugs
Corticosteroids / cortisone-replacement
Drugs metabolized by CYP3A (e.g. some statins, certain antiretrovirals)

Side Effects:

Injection-site reactions (erythema, pruritus, pain, irritation, swelling, bruising)Arthralgia / joint pain, myalgia, peripheral edema (GH-excess type effects)Increased fasting glucose / reduced insulin sensitivity

Want to compare more supplements?

Loading comparison...